The momentum behind ibogaine research in the United States just took another significant leap forward. In a single week, three new states introduced legislation aimed at funding ibogaine research, bringing the total number of states with active ibogaine-related bills to at least ten. For anyone who has been watching this space — or considering ibogaine treatment themselves — this is one of the most encouraging policy developments we have seen in years.
Tennessee State Senator Page Walley, a Republican, introduced SB 2149, known as the "Helping Open Pathways to Effective Treatment Act," or the HOPE Act. The bill would establish the Tennessee Mental Health Innovation Fund, designed to leverage public-private partnerships specifically for ibogaine research. The name alone tells you something about the shift happening in conservative legislatures — ibogaine is no longer a fringe topic, it is being framed as a pathway to hope for people who have run out of conventional options. In Maryland, Democratic State Senator Kevin Harris introduced SB 527, which would allocate $1.
Tennessee State Senator Page Walley, a Republican, introduced SB 2149, known as the "Helping Open Pathways to Effective Treatment Act," or the HOPE Act.
5 million from the state's Opioid Restitution Fund for ibogaine research. Maryland is set to receive roughly $670 million from prescription opioid legal settlements over the next decade, and this bill represents one of the first attempts to direct a portion of that money toward ibogaine specifically. It is a meaningful step — using the financial consequences of the opioid crisis to fund what many researchers believe could be one of its most powerful solutions. Vermont rounded out the week with H0859, a bill introduced by six state representatives that would establish a psychedelic advisory board.
Begin Your Journey
MindScape Retreat offers medically supervised ibogaine treatment in Cozumel, Mexico. Speak with our clinical team to learn if you are a candidate.
The bill explicitly references Americans for Ibogaine, the national advocacy consortium co-founded by former Texas Governor Rick Perry, and frames the board as a step toward the eventual medicalization and FDA approval of ibogaine. From MindScape Retreat's clinical perspective, this wave of legislation validates what we observe every day in our treatment facility. The patients who come to us in Cozumel — many of them after years of failed conventional treatments — consistently report profound breakthroughs. Research suggests that ibogaine addresses addiction at a neurological level that most other treatments simply cannot reach, resetting receptors and interrupting craving patterns in ways that medications like Suboxone and methadone were never designed to do.
Our medical team, which includes on-site physicians and nurses providing 24/7 cardiac monitoring, has seen this firsthand across hundreds of treatment protocols. The fact that both Republican and Democratic lawmakers are championing ibogaine research is particularly significant. This is not a partisan issue. The opioid crisis does not discriminate, and neither should the search for effective treatments.
Many families report that ibogaine gave their loved ones a second chance when nothing else worked — and the growing legislative support suggests that policymakers are finally listening. We believe the day is coming when Americans will not have to travel internationally for medically supervised ibogaine treatment. Until then, MindScape Retreat continues to provide safe, comprehensive ibogaine programs with the kind of medical oversight that these new research programs are being designed to study. Sources: The Microdose / UC Berkeley Center for the Science of Psychedelics; Psychedelic Alpha Considering ibogaine treatment?
[Learn about MindScape Retreat's medically supervised program →](https://mindscaperetreat.